1-20 of 117
Jacob P Laubach
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Joshua Richter, Sheeba K. Thomas, Amrita Y Krishnan, Jacob P. Laubach, Adam D. Cohen, Suzanne Trudel, Luciano J. Costa, Nizar J. Bahlis, Peter A. Forsberg, Rayan Kaedbey, Rafael Fonseca, Andrew Spencer, Paula Rodríguez-Otero, Maria-Victoria Mateos, Chihunt Wong, James Cooper, Tulika Tyagi, Rin Nakamura, Voleak Choeurng, Alexander M. Lesokhin
Journal: Blood
Blood (2024) 144 (Supplement 1): 1021.
https://doi.org/10.1182/blood-2024-199542
Published: 2024
Journal Articles

Elranatamab in Patients with Daratumumab Relapsed and/or Refractory Light Chain Amyloidosis

Pedro G Vianna, Shahrier Hossain, Shannon Miller, Annemarie Rossi, Sarah AM Cuddy, Rodney H Falk, Jacob P. Laubach, Giada Bianchi
Journal: Blood
Blood (2024) 144 (Supplement 1): 3304.
https://doi.org/10.1182/blood-2024-200933
Published: 2024
Journal Articles

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Sophie Magidson, Robert A. Redd, Jacob P. Laubach, Clifton C. Mo, Elizabeth K. O'Donnell, Adam S. Sperling, Monique A. Hartley-Brown, Shonali Midha, Yuxin Liu, Frances Arters, Marjorie Marto, Christine Davie, Caroline Ricciardi, Dechen Choden, Ashlee Strutevant, Jillian Alberti, Amy Goguen, Michael Constantine, Pedro Sanz-Altamira, Lorenzo Trippa, Nikhil C. Munshi, Kenneth C. Anderson, Paul G. Richardson, Irene Ghobrial
Journal: Blood
Blood (2024) 144 (Supplement 1): 3360.
https://doi.org/10.1182/blood-2024-202653
Published: 2024
Journal Articles

Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies

Rosa Toenges, Jean-Baptiste Alberge, Francesco Corrado, Nayda Bidikian, David M. Cordas Dos Santos, Ankit K. Dutta, Elizabeth D. Lightbody, Romanos Sklavenitis Pistofidis, Adam S. Sperling, Kenneth C. Anderson, Shonali Midha, Yuxin Liu, Jacob P. Laubach, Eric L. Smith, Nikhil C. Munshi, Omar Nadeem, Irene Ghobrial, Gad Getz
Journal: Blood
Blood (2024) 144 (Supplement 1): 492.
https://doi.org/10.1182/blood-2024-204132
Published: 2024
Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Christiane A. Houde, Abdullah Khan, Susanna J. Jacobus, Hani Hassoun, Larry D. Anderson, Jr., Lauren E. Merz, Rebecca L. Zon, Yvonne Efebera, Tondre Buck, Racquel D. Innis-Shelton, Monique A Hartley-Brown, Sagar Lonial, Erica L. Campagnaro, Peter M. Voorhees, Robert Z. Orlowski, Edward Libby, David Duane Hurd, Caitlin L. Costello, Noopur S. Raje, Eva Medvedova, Philip L. McCarthy, Carter P. Milner, Cristina Gasparetto, Mounzer E Agha, Krisstina Gowin, Rammurti T. Kamble, Sundar Jagannath, Nitya Nathwani, Melissa Alsina, Sergio A. Giralt, Jacob P. Laubach, Omar Nadeem, Irene M. Ghobrial, Clifton C. Mo, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C Munshi, Paul G. Richardson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4762.
https://doi.org/10.1182/blood-2023-181032
Published: 2023
Journal Articles

Ibrutinib in Combination with Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma (AFT-15)

Yvonne Efebera, Vera Jean Suman, Shira N. Dinner, Ashley E Rosko, John T Mckay, Peter Barth, Patrick Hagen, Saad Z Usmani, Paul G. Richardson, Jacob P. Laubach
Journal: Blood
Blood (2023) 142 (Supplement 1): 3340.
https://doi.org/10.1182/blood-2023-187296
Published: 2023
Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Natalie Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob P Laubach, Timothy Martin Schmidt, Douglas W Sborov, Eva Medvedova, Brandi Reeves, Binod Dhakal, Cesar Rodriguez, Saurabh Chhabra, Ajai Chari, Susan Bal, Larry D. Anderson, Jr., Bhagirathbhai Dholaria, Nitya Nathwani, Parameswaran Hari, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Ken H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Smith Giri, Luciano J. Costa, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 10144–10147.
https://doi.org/10.1182/blood-2022-160451
Published: 2022
Journal Articles

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Hani Hassoun, Susanna J. Jacobus, Paul G. Richardson, Jeffrey A. Zonder, Peter M. Voorhees, Jonathan L. Kaufman, Andrew J. Yee, Emma C. Scott, Pallawi Torka, Edward Libby, Brandi Reeves, Michael L. Wang, Larry D. Anderson, Jr., Carter Milner, Cristina J. Gasparetto, Mounzer Agha, Abdullah Khan, David Duane Hurd, David Avigan, Caitlin Costello, Andrzej Jakubowiak, Sagar Lonial, Noopur Raje, Eva Medvedova, Philip L. McCarthy, Robert Z. Orlowski, Omar Nadeem, Jacob P. Laubach, Marcelo C. Pasquini, Sergio A. Giralt, Kelly Masone, Mehmet K. Samur, Aurore Perrot, Philippe Moreau, Herve Avet-Loiseau, Edie A. Weller, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood
Blood (2022) 140 (Supplement 1): 4834–4838.
https://doi.org/10.1182/blood-2022-162741
Published: 2022
Journal Articles

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Alexander M Lesokhin, Joshua Richter, Suzanne Trudel, Adam D Cohen, Andrew Spencer, Peter A Forsberg, Jacob P Laubach, Sheeba K Thomas, Nizar J. Bahlis, Luciano J. Costa, Paula Rodriguez Otero, Maria-Victoria Mateos, Jesus G Berdeja, Rayan Kaedbey, Amrita Y. Krishnan, Rafael Fonseca, Voleak Choeurng, James Cooper, Teiko Sumiyoshi, Chihunt Wong, Simon J Harrison
Journal: Blood
Blood (2022) 140 (Supplement 1): 4415–4417.
https://doi.org/10.1182/blood-2022-157547
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Ajai Chari, Jonathan L. Kaufman, Jacob P Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 7278–7281.
https://doi.org/10.1182/blood-2022-162339
Published: 2022
Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

Jacob P. Laubach, Jonathan L. Kaufman, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Luciano J. Costa, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Yvonne A. Efebera, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, J Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhees
Journal: Blood
Blood (2021) 138 (Supplement 1): 79.
https://doi.org/10.1182/blood-2021-149024
Published: 2021
Journal Articles

Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma

Elizabeth K. O'Donnell, Yael Shapiro, Omar Nadeem, Andrew J. Yee, Jacob P. Laubach, Andrew R. Branagan, Kenneth C. Anderson, Clifton C. Mo, Nikhil C. Munshi, Irene M. Ghobrial, Adam S. Sperling, Emerentia Agyemang, Cynthia C. Harrington, Jill N. Burke, Paul G. Richardson, Noopur S. Raje, Areej El-Jawahri
Journal: Blood
Blood (2021) 138 (Supplement 1): 4082.
https://doi.org/10.1182/blood-2021-146342
Published: 2021
Journal Articles

B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Robert A. Redd, Julia Prescott, Amada Metivier, Kelsey Tague, Veronica Romines, Meredith Bertoni, Alexandra Savell, Rebekah Medina, Alexandra Distaso, Houry Leblebjian, Clifton C. Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial
Journal: Blood
Blood (2021) 138 (Supplement 1): 4782.
https://doi.org/10.1182/blood-2021-148023
Published: 2021
Journal Articles

A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)

Elizabeth K. O'Donnell, Vera Jean Suman, Susan M. Geyer, Omar Nadeem, Shira Dinner, Andrew J. Yee, Jacob P. Laubach, Clifton C. Mo, Sascha A. Tuchman, Kristen Donadio, Sarah Sinclair, Noopur S. Raje, Paul G. Richardson
Journal: Blood
Blood (2021) 138 (Supplement 1): 4776.
https://doi.org/10.1182/blood-2021-146274
Published: 2021
Journal Articles

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Elizabeth K. O'Donnell, Clifton C. Mo, Andrew J. Yee, Omar Nadeem, Andrew R. Branagan, Jacob P. Laubach, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Cynthia C. Harrington, Emerentia Agyemang, Kerry Spillane, Brenton LaStofka, Jacalyn Rosenblatt, Noopur S. Raje, Paul G. Richardson
Journal: Blood
Blood (2021) 138 (Supplement 1): 5043.
https://doi.org/10.1182/blood-2021-146284
Published: 2021
Journal Articles

A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Robert A. Redd, Julia Prescott, Kelsey Tague, Veronica Romines, Amada Metivier, Alexandra Savell, Houry Leblebjian, Alexandra Distaso, Clifton C Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial
Journal: Blood
Blood (2021) 138 (Supplement 1): 2749.
https://doi.org/10.1182/blood-2021-149787
Published: 2021
Journal Articles

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

Saurabh Chhabra, Natalie S. Callander, Luciano J. Costa, Jonathan L. Kaufman, Jacob P. Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Bhagirathbhai Dholaria, Huiling Pei, Annelore Cortoos, Sharmila Patel, J Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhees
Journal: Blood
Blood (2021) 138 (Supplement 1): 2852.
https://doi.org/10.1182/blood-2021-149028
Published: 2021
Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin

Larry D. Anderson, Jr., Jonathan L. Kaufman, Jacob P. Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Luciano J. Costa, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, J Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Peter M. Voorhees, Paul G. Richardson
Journal: Blood
Blood (2021) 138 (Supplement 1): 2723.
https://doi.org/10.1182/blood-2021-148533
Published: 2021
Journal Articles

Mapping Myeloma: A Roadmap of Daratumumab Use in Clinical Pathways

Shahrier Hossain, Houry Leblebjian, David M Jackman, Jacob P. Laubach, Clifton C. Mo, Paul G. Richardson, Emily Foster, Ariel Martin-Quashie, Robert Redd, Omar Nadeem
Journal: Blood
Blood (2021) 138 (Supplement 1): 4021.
https://doi.org/10.1182/blood-2021-149482
Published: 2021
Journal Articles

Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform

Adam S. Sperling, Sarah Nikiforow, Omar Nadeem, Clifton C Mo, Jacob P. Laubach, Kenneth C. Anderson, Alejandro Alonso, Shuntaro Ikegawa, Rao Prabhala, Diego Hernandez Rodriguez, Heather Daley, Kit L. Shaw, Yohei Arihara, Soudeh Ansari, David S Quinn, David Pearson, Anniesha Hack, Louise M Treanor, Dexiu Bu, Jennifer Mataraza, Lawrence Rispoli, Marc Credi, Jerome Ritz, Serena De Vita, Nikhil C. Munshi
Journal: Blood
Blood (2021) 138 (Supplement 1): 3864.
https://doi.org/10.1182/blood-2021-146646
Published: 2021